The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis

Nature Reviews Neurology

Volumn 13, Issue 5, 2017, Pages 290-301

  Van Sonderen, Agnes ^a,b   Petit Pedrol, Mar ^c,d   Dalmau, Josep ^c,d,e,f   Titulaer, Maarten J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Centro de Investigación Biomédica en Red de Cáncer CIBERONC University of Barcelona   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AUTOANTIBODY; CASPR2 ANTIBODY; CASPR2 PROTEIN; CELL ADHESION MOLECULE; IMMUNOMODULATING AGENT; LGI1 ANTIBODY; LGI1 PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL ANTIBODY; CNTNAP2 PROTEIN, HUMAN; LGI1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN; PROTEIN;

ANTIBODY SPECIFICITY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEIZURE; SYNDROME; AGONISTS; ANIMAL; IMMUNOLOGY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; ENCEPHALITIS; HUMANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEINS;

EID: 85017650845     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2017.43     Document Type: Review

References (81)

1. van Coevorden-Hameete, M. H., de Graaff, E., Titulaer, M. J., Hoogenraad, C. C. & Sillevis Smitt, P. A. Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun. Rev. 13, 299-312 (2014).
2. Dalmau, J. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61, 25-36 (2007).
3. Lai, M. et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 65, 424-434 (2009).
4. Lancaster, E. & Dalmau, J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 8, 380-390 (2012).
5. Irani, S. R. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133, 2734-2748 (2010).
6. Lai, M. et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 9, 776-785 (2010).
7. Shillito, P. et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38, 714-722 (1995).
8. Isaacs, H. A syndrome of continuous muscle-fibre activity. J. Neurol. Neurosurg. Psychiatry 24, 319-325 (1961).
9. Barber, P. A., Anderson, N. E. & Vincent, A. Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 54, 771-772 (2000).
10. Buckley, C. et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol. 50, 73-78 (2001).
11. van Sonderen, A. et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 87, 1449-1456 (2016).
12. Sagane, K., Ishihama, Y. & Sugimoto, H. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11. Int. J. Biol. Sci. 4, 387-396 (2008).
13. Zhou, Y. D. et al. Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat. Med. 15, 1208-1214 (2009).
14. Kole, M. J. et al. Selective loss of presynaptic potassium channel clusters at the cerebellar basket cell terminal pinceau in adam11 mutants reveals their role in ephaptic control of Purkinje cell firing. J. Neurosci. 35, 11433-11444 (2015).
15. Kalachikov, S. et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat. Genet. 30, 335-341 (2002).
16. Morante-Redolat, J. M. et al. Mutations in the LGI1/ Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum. Mol. Genet. 11, 1119-1128 (2002).
17. Fukata, Y. et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 313, 1792-1795 (2006).
18. Fukata, Y. et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc. Natl Acad. Sci. USA 107, 3799-3804 (2010).
19. Ohkawa, T. et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J. Neurosci. 33, 18161-18174 (2013).
20. Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30, 5866-5875 (2010).
21. Peng, X. et al. Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann. Neurol. 77, 381-398 (2015).
22. Arino, H. et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 87, 759-765 (2016).
23. Irani, S. R. et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann. Neurol. 72, 241-255 (2012).
24. Bien, C. G. et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135, 1622-1638 (2012).
25. Gao, L. et al. Clinical characterization of autoimmune LGI1 antibody limbic encephalitis. Epilepsy Behav. 56, 165-169 (2016).
26. Irani, S. R. et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann. Neurol. 69, 892-900 (2011).
27. Li, Z., Cui, T., Shi, W. & Wang, Q. Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures. Medicine (Baltimore) 95, e4244 (2016).
28. Olberg, H., Haugen, M., Storstein, A. & Vedeler, C. A. Neurological manifestations related to level of voltage-gated potassium channel antibodies. J. Neurol. Neurosurg. Psychiatry 84, 941-943 (2013).
29. Paterson, R. W., Zandi, M. S., Armstrong, R., Vincent, A. & Schott, J. M. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J. Neurol. Neurosurg. Psychiatry 85, 625-630 (2014).
30. Shin, Y. W. et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J. Neuroimmunol. 265, 75-81 (2013).
31. Navarro, V. et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 139, 1079-1093 (2016).
32. Rocamora, R. et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 23, 670-673 (2014).
33. Iranzo, A. et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann. Neurol. 59, 178-181 (2006).
34. Finke, C. et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol. 74, 50-59 (2017).
35. Flanagan, E. P. et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol. Neuroimmunol. Neuroinflamm. 2, e161 (2015).
36. Andrade, D. M., Tai, P., Dalmau, J. & Wennberg, R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 76, 1355-1357 (2011).
37. Steriade, C., Mirsattari, S. M., Murray, B. J. & Wennberg, R. Subclinical temporal EEG seizure pattern in LGI1-antibody-mediated encephalitis. Epilepsia 57, e155-e160 (2016).
38. Malter, M. P. et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J. Neurol. 261, 1695-1705 (2014).
39. Irani, S. R. et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136, 3151-3162 (2013).
40. Huijbers, M. G. et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur. J. Neurol. 22, 1151-1161 (2015).
41. Irani, S. R., Gelfand, J. M., Bettcher, B. M., Singhal, N. S. & Geschwind, M. D. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol. 71, 896-900 (2014).
42. Hacohen, Y. et al. Clinical relevance of voltage-gated potassium channel-complex antibodies in children. Neurology 85, 967-975 (2015).
43. Borusiak, P. et al. Autoantibodies to neuronal antigens in children with focal epilepsy and no prima facie signs of encephalitis. Eur. J. Paediatr. Neurol. 20, 573-579 (2016).
44. Lin, J. J. et al. VGKC complex antibodies in pediatric severe acute encephalitis: a study and literature review. Brain Dev. 35, 630-635 (2013).
45. Suleiman, J. et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 76, 1252-1255 (2011).
46. Suleiman, J., Brilot, F., Lang, B., Vincent, A. & Dale, R. C. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia 54, 1036-1045 (2013).
47. Wright, S. et al. Neuronal antibodies in pediatric epilepsy: clinical features and long-term outcomes of a historical cohort not treated with immunotherapy. Epilepsia 57, 823-831 (2016).
48. Traka, M. et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J. Cell Biol. 162, 1161-1172 (2003).
49. Poliak, S. et al. Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J. Cell Biol. 162, 1149-1160 (2003).
50. Rasband, M. N. et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J. Neurosci. 18, 36-47 (1998).
51. Devaux, J. & Gow, A. Tight junctions potentiate the insulative properties of small CNS myelinated axons. J. Cell Biol. 183, 909-921 (2008).
52. Penagarikano, O. et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147, 235-246 (2011).
53. Anderson, G. R. et al. Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc. Natl Acad. Sci. USA 109, 18120-18125 (2012).
54. Rodenas-Cuadrado, P., Ho, J. & Vernes, S. C. Shining a light on CNTNAP2: complex functions to complex disorders. Eur. J. Hum. Genet. 22, 171-178 (2014).
55. Olsen, A. L., Lai, Y., Dalmau, J., Scherer, S. S. & Lancaster, E. Caspr2 autoantibodies target multiple epitopes. Neurol. Neuroimmunol. Neuroinflamm. 2, e127 (2015).
56. Pinatel, D. et al. Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. Front. Cell. Neurosci. 9, 265 (2015).
57. van Sonderen, A. et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87, 521-528 (2016).
58. Kortvelyessy, P. et al. Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 2, e75 (2015).
59. Joubert, B. et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 73, 1115-1124 (2016).
60. Lancaster, E. et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann. Neurol. 69, 303-311 (2011).
61. Becker, E. B. et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J. Neurol. Neurosurg. Psychiatry 83, 437-440 (2012).
62. Sunwoo, J. S. et al. Clinical manifestations of patients with CASPR2 antibodies. J. Neuroimmunol. 281, 17-22 (2015).
63. Torres-Vega, E. et al. Netrin1-receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology 88, 1235-1242(2017).
64. Bien, C. G. et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur. J. Neurol. 24, 175-186 (2017).
65. van Sonderen, A., Arino, H., Dalmau, J. & Titulaer, M. J. Author response: the clinical spectrum of Caspr2 antibody-associated disease. Neurology 88, 333-334 (2017).
66. Kim, S. Y. et al. Screening autoimmune anti-neuronal antibodies in pediatric patients with suspected autoimmune encephalitis. J. Epilepsy Res. 4, 55-61 (2014).
67. Hart, I. K., Maddison, P., Newsom-Davis, J., Vincent, A. & Mills, K. R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125, 1887-1895 (2002).
68. Klein, C. J., Lennon, V. A., Aston, P. A., McKeon, A. & Pittock, S. J. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 79, 1136-1144 (2012).
69. Fujita, K. et al. Voltage-gated potassium channel complex antibodies in Creutzfeldt-Jakob disease. J. Neurol. 259, 2249-2250 (2012).
70. Huda, S. et al. An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J. Neurol. 262, 418-424 (2015).
71. van Sonderen, A. et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 86, 1692-1699 (2016).
72. Lahoria, R. et al. Clinical-pathologic correlations in VGKC-subtyped autoimmune painful polyneuropathy. Muscle Nerve http: //dx. doi. org/10. 1002/mus. 25371 (2016).
73. Zandi, M. S. et al. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 258, 686-688 (2011).
74. Graus, F. & Gorman, M. P. Voltage-gated potassium channel antibodies: game over. Neurology 86, 1657-1658 (2016).
75. O'Sullivan, B. J. et al. When should we test for voltage-gated potassium channel complex antibodies? A retrospective case control study. J. Clin. Neurosci. 33, 198-204 (2016).
76. Kotsenas, A. L. et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am. J. Neuroradiol. 35, 84-89 (2014).
77. Lilleker, J. B., Jones, M. S. & Mohanraj, R. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 22, 776-779 (2013).
78. Boronat, A. et al. Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. J. Neuroimmunol. 244, 103-106 (2012).
79. Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391-404 (2016).
80. Haberlandt, E. et al. Limbic encephalitis in children and adolescents. Arch. Dis. Child. 96, 186-191 (2011).
81. Dhamija, R. et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr. Neurol. 44, 275-281 (2011).